

Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	teplizumab
Brand name	Tziel®
Dosage form(s)	1 mg/mL, injection for intravenous infusion
Manufacturer	Sanofi-Aventis Canada inc.
Submission type	New Submission
Indication reviewed	To delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 8 years of age and older with Stage 2 T1D.
Canada's Drug Agency (CDA-AMC) Clinical Reimbursement Reviews (CRR)	The Canadian Drug Expert Committee (CDEC) recommended: Do Not Reimburse . Visit the CDA-AMC website for more details .
Ministry of Health (the Ministry) Review	The Ministry reviewed clinical and pharmacoeconomic combined reports prepared by the CDA-AMC's CRR, including clinical and pharmacoeconomic evidence review material and the recommendations of the CDEC. The Ministry also considered patient input provided to CDEC and received Your Voice patient input questionnaire responses from 2 patients, 6 caregivers, and 2 patient groups.
Drug Coverage Decision	Non-benefit
Date	May 8, 2026
Reasons	Drug coverage decision is consistent with the CDEC recommendation that Tziel not be reimbursed to delay the onset of Stage 3 T1D in adult and pediatric patients 8 years of age and older with Stage 2 T1D.

- Evidence from 1 clinical trial demonstrated that Tziel likely resulted in delaying the time to progress to Stage 3 T1D by approximately 2 years compared to placebo. However, it remains uncertain whether the delay in progression to Stage 3 T1D translates into long-term clinical benefits (e.g., reduced risk of macrovascular and microvascular complications).
- Short-term safety data show Tziel can cause side effects, including serious ones, and there's no information on long-term safety or its impact on quality of life.
- Based on economic considerations and the submitted product price, there was substantial uncertainty regarding the drug's cost-effectiveness and whether it offers value for money.

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process. As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether funding it provides good value
- ethical considerations of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.